Liver Cirrhosis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt

DelveInsight’s “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Liver Cirrhosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cirrhosis Market Forecast

Some of the key facts of the Liver Cirrhosis Market Report: 

• The Liver Cirrhosis market size was valued approximately USD 3 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to CDC statistics, liver cirrhosis is more prevalent in US individuals between the ages of 45 and 64
• Cirrhosis was linked to 2.4% of global fatalities in 2019, according to a study on the global epidemiology of cirrhosis by Huang et al. (2023). According to a study, non-alcoholic fatty liver disease (NAFLD) and alcohol-associated cirrhosis are becoming more common in many parts of the world, despite the fact that viral hepatitis is the primary cause of cirrhosis globally
• According to the Prevalence of Chronic Liver Disease in the General Population of Northern Italy: The Dionysos Study, 37% of cases of cirrhosis were primarily brought on by the hepatitis B or C virus, and 26% were brought on by alcohol
• According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), around 1 in 200 Americans aged 45 to 54 have cirrhosis
• There are several different medications in the current liver cirrhosis drug pipeline. The most prominent medications for this indication include Belapectin, Resmetirom, Efruxifermin, LPCN 1148, Saroglitazar Magnesium, and several more. Current trials and ongoing research have the power to alter the market
• Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
• The Liver Cirrhosis epidemiology based on gender analyzed that males are more affected with Liver Cirrhosis than females
• The Liver Cirrhosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cirrhosis pipeline products will significantly revolutionize the Liver Cirrhosis market dynamics.

Liver Cirrhosis Overview

A late-stage liver condition called liver cirrhosis causes the liver to become irreversibly damaged when good liver tissue is replaced with scar tissue.

Get a Free sample for the Liver Cirrhosis Market Report 

https://www.delveinsight.com/report-store/liver-cirrhosis-market

Liver Cirrhosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Cirrhosis Epidemiology Segmentation:

The Liver Cirrhosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Liver Cirrhosis
• Prevalent Cases of Liver Cirrhosis by severity
• Gender-specific Prevalence of Liver Cirrhosis
• Diagnosed Cases of Episodic and Chronic Liver Cirrhosis

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ Liver Cirrhosis Epidemiology Forecast

Liver Cirrhosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cirrhosis market or expected to get launched during the study period. The analysis covers Liver Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Cirrhosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Cirrhosis Therapies and Key Companies

• Resmetirom: Madrigal Pharmaceuticals Inc.
• Belapectin: Galectin Therapeutics
• Efruxifermin: AkeroTherapeutics
• LPCN 1148: Lipocine Inc
• IDN-6556: Conatus Pharma
• NRL972: Norgine
• Resmetirom: Madrigal Pharma
• GXHPC1: Gwo Xi Stem Cell Applied Tech
• GI262570: GlaxoSmithKline
• Rifaximin: Bausch Health
• BMS-986263: Bristol-Myers Squibb
• MNK6106: Mallinckrodt
• conivaptan: Cumberland Pharma
• LPCN 1148: Lipocine Inc.
• INT-747: Intercept Pharma
• Satavaptan: Sanofi
• oltipraz: HK inno.N Corporation
• Obeticholic Acid (OCA): Intercept Pharma
• IDN-6556: Conatus Pharmaceuticals Inc.
• Pregabalin: Pfizer

Discover more about therapies set to grab major Liver Cirrhosis market share @ Liver Cirrhosis Treatment Market

Scope of the Liver Cirrhosis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
• Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
• Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Liver Cirrhosis Unmet Needs, KOL’s views, Analyst’s views, Liver Cirrhosis Market Access and Reimbursement 

To know more about Liver Cirrhosis companies working in the treatment market, visit @ Liver Cirrhosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Liver Cirrhosis Market Report Introduction

2. Executive Summary for Liver Cirrhosis

3. SWOT analysis of Liver Cirrhosis

4. Liver Cirrhosis Patient Share (%) Overview at a Glance

5. Liver Cirrhosis Market Overview at a Glance

6. Liver Cirrhosis Disease Background and Overview

7. Liver Cirrhosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cirrhosis 

9. Liver Cirrhosis Current Treatment and Medical Practices

10. Liver Cirrhosis Unmet Needs

11. Liver Cirrhosis Emerging Therapies

12. Liver Cirrhosis Market Outlook

13. Country-Wise Liver Cirrhosis Market Analysis (2019–2032)

14. Liver Cirrhosis Market Access and Reimbursement of Therapies

15. Liver Cirrhosis Market Drivers

16. Liver Cirrhosis Market Barriers

17.  Liver Cirrhosis Appendix

18. Liver Cirrhosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services